Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Pearl Therapeutics

AstraZeneca AZ

AZ’s Farxiga gets heart failure prevention okay from FDA

Important win for AZ as it chases down market leader Jardiance

- PMLiVE

AZ and Daiichi get speedy review for rival to Roche’s HER2 drugs

Could add to AZ's portfolio of emerging cancer drugs

AstraZeneca AZ

AstraZeneca sells Losec rights as part of refocus strategy

Funds will be diverted to bolster main therapy areas

- PMLiVE

GSK’s Zejula challenges AZ/Merck’s Lynparza in PARP inhibitor category

New data in ovarian cancer creates potential for market battle

- PMLiVE

Innate Pharma and AstraZeneca take monalizumab into phase 3

AZ hopes to catch up to rivals using the French biotech's candidate

AstraZeneca AZ

FDA fast-tracks AstraZeneca’s Farxiga in heart failure

Races to become first-in-class

AstraZeneca AZ

Can AZ’s Imfinzi challenge Tecentriq in small cell lung cancer?

New data shows improvement in overall survival

- PMLiVE

AZ unveils phase 3 Brilinta data in CAD and type 2 diabetes

Reduces CV events but falls down on increased bleeding risk

- PMLiVE

AZ’s Farxiga heart failure results wow the ESC

Chases after market leader Jardiance

AstraZeneca AZ

Second TULIP trial resurrects AZ’s lupus drug anifrolumab

Will now decide whether to file treatment for approval

- PMLiVE

‘Therapeutic overcrowding’ could hit big pharma returns

Jefferies analysts identify most at-risk companies

AstraZeneca AZ

AZ builds case for its COPD triple as it chases GSK’s Trelegy

Awaiting approvals in Europe and the US

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links